Literature DB >> 31185387

Prognostic value of body composition on recurrence and survival of advanced-stage head and neck cancer.

Ah Ra Jung1, Jong-Lyel Roh2, Jae Seung Kim3, Sung-Bae Kim4, Seung-Ho Choi1, Soon Yuhl Nam1, Sang Yoon Kim1.   

Abstract

BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is commonly associated with a high risk of malnutrition and sarcopenia, related to adverse clinical outcomes. This study evaluated the prognostic values of body composition on recurrence and survival in patients with advanced-stage HNSCC.
METHODS: This study prospectively enrolled 258 consecutive patients with definitive treatments for advanced-stage HNSCC. For the determination of sarcopenia, the cross-sectional area of the skeletal muscles (SMs) was measured at the level of the third lumbar vertebra on the computed tomography images of whole-body 18F-fluorodeoxyglucose positron-emission tomography/computed tomography before and after treatments. Univariate and multivariate Cox proportional hazards regression analyses were performed to identify the prognostic factors of disease-free survival (DFS) and overall survival (OS).
RESULTS: Pretreatment and post-treatment diminished SM masses (sarcopenia) were found in 17 (6.6%) and 32 (12.4%) of 258 included patients, respectively. All values of body composition, SM index, visceral fat area, lean body mass, fat mass and body mass index significantly decreased after treatment (all P < 0.05). Multivariable analyses showed that age, Charlson comorbidity index, pretreatment and post-treatment sarcopenia, pretreatment hypoalbuminaemia, p16 status and tumour site remained the independent variables predictive of DFS and OS outcomes (all P < 0.05). Patients with sarcopenia before or after treatment had about threefold increased risk of overall recurrence or death.
CONCLUSION: Diminished SM mass may predict recurrence and survival after definitive treatments in patients with advanced-stage HNSCC.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Body composition; Head and neck squamous cell carcinoma; Prognosis; Sarcopenia; Skeletal muscle index

Mesh:

Year:  2019        PMID: 31185387     DOI: 10.1016/j.ejca.2019.05.006

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  15 in total

Review 1.  Adiposity and cancer survival: a systematic review and meta-analysis.

Authors:  Elizabeth M Cespedes Feliciano; Bette J Caan; En Cheng; Jocelyn Kirley
Journal:  Cancer Causes Control       Date:  2022-08-15       Impact factor: 2.532

2.  Sarcopenia is associated with higher toxicity and poor prognosis of nasopharyngeal carcinoma.

Authors:  Xin Hua; Jun-Fang Liao; Xin Huang; Han-Ying Huang; Wen Wen; Zhi-Qing Long; Ling Guo; Zhong-Yu Yuan; Huan-Xin Lin
Journal:  Ther Adv Med Oncol       Date:  2020-08-18       Impact factor: 8.168

3.  Modeling Sarcopenia to Predict Survival for Patients With Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy.

Authors:  Xin Hua; Wang-Zhong Li; Xin Huang; Wen Wen; Han-Ying Huang; Zhi-Qing Long; Huan-Xin Lin; Zhong-Yu Yuan; Ling Guo
Journal:  Front Oncol       Date:  2021-03-11       Impact factor: 6.244

4.  Bioelectrical impedance analysis as a quantitative measure of sarcopenia in head and neck cancer patients treated with radiotherapy.

Authors:  Aaron J Grossberg; Crosby D Rock; Jared Edwards; Abdallah S R Mohamed; Debra Ruzensky; Angela Currie; Patricia Rosemond; Jack Phan; G Brandon Gunn; Steven J Frank; William H Morrison; Adam S Garden; Clifton D Fuller; David I Rosenthal
Journal:  Radiother Oncol       Date:  2021-03-15       Impact factor: 6.901

5.  Sarcopenia as a prognostic factor in patients with recurrent pancreatic cancer: a retrospective study.

Authors:  Teruhisa Sakamoto; Takuki Yagyu; Ei Uchinaka; Kozo Miyatani; Takehiko Hanaki; Kyoichi Kihara; Tomoyuki Matsunaga; Manabu Yamamoto; Naruo Tokuyasu; Soichiro Honjo; Yoshiyuki Fujiwara
Journal:  World J Surg Oncol       Date:  2020-08-22       Impact factor: 2.754

6.  Impact of Body Composition on the Risk of Hepatocellular Carcinoma Recurrence After Liver Transplantation.

Authors:  Karolina Grąt; Ryszard Pacho; Michał Grąt; Marek Krawczyk; Krzysztof Zieniewicz; Olgierd Rowiński
Journal:  J Clin Med       Date:  2019-10-13       Impact factor: 4.241

7.  Low skeletal muscle mass predicts relevant clinical outcomes in head and neck squamous cell carcinoma. A meta analysis.

Authors:  Alexey Surov; Andreas Wienke
Journal:  Ther Adv Med Oncol       Date:  2021-05-13       Impact factor: 8.168

8.  Preoperative C-Reactive Protein/Albumin Ratio is a Prognostic Indicator for Survival in Surgically Treated Gastrointestinal Stromal Tumors: A Retrospective Cohort Study.

Authors:  Xianglong Cao; Jian Cui; Zijian Li; Gang Zhao
Journal:  Cancer Manag Res       Date:  2021-05-24       Impact factor: 3.989

9.  The predictive and prognostic value of low skeletal muscle mass for dose-limiting toxicity and survival in head and neck cancer patients receiving concomitant cetuximab and radiotherapy.

Authors:  L F J Huiskamp; N Chargi; L A Devriese; P A de Jong; R de Bree
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-04-25       Impact factor: 2.503

10.  Low Skeletal Muscle Mass Impairs Quality of Life in Nasopharyngeal Carcinoma Patients Treated With Concurrent Chemoradiotherapy.

Authors:  Xin Hua; Jun-Fang Liao; Shan Liu; Jun Zhang; Han-Ying Huang; Wen Wen; Zhi-Qing Long; Wen-Wen Zhang; Ling Guo; Huan-Xin Lin
Journal:  Front Nutr       Date:  2020-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.